The Clinical Pharmacology of Etoposide and Teniposide

@article{Clark1987TheCP,
  title={The Clinical Pharmacology of Etoposide and Teniposide},
  author={Peter I. Clark and Maurice L. Slevin},
  journal={Clinical Pharmacokinetics},
  year={1987},
  volume={12},
  pages={223-252}
}
  • P. Clark, M. Slevin
  • Published 1 April 1987
  • Chemistry, Medicine
  • Clinical Pharmacokinetics
SummaryEtoposide and teniposide are semisynthetic derivatives of podophyllotoxin and are increasingly used in cancer medicine. Teniposide is more highly protein-bound than etoposide, and its uptake and binding to cells is also greater. Etoposide and teniposide are phase-specific cytotoxic drugs acting in the late S and early G2 phases of the cell cycle. They appear to act by causing breaks in DNA via an interaction with DNA topoisomerase II or by the formation of free radicals. Teniposide is… Expand
The Pharmacokinetics of Epipodopyllotoxins — Clinical Relevance
TLDR
It is possible that the optimal etoposide schedule and dose varies from patient to patient and tumor to tumor depending on the intra-individual capacities for clearance and metabolization and on the variable proportion of cycling cells open to attack by such a phase-specific action of VP-16. Expand
Oral Etoposide
TLDR
Oral etoposide has been demonstrated to be effective in the treatment of SCLC and offers a reasonable and cost-effective outpatient alternative for this group of patients. Expand
Camptothecin and Podophyllotoxin Derivatives
TLDR
Camptothecins, irinotecan, etoposide and teniposide are degraded via complex metabolic pathways, and the extent of catechol formation over time during drug metabolism may be associated with a higher risk for secondary malignancies. Expand
Increased teniposide clearance with concomitant anticonvulsant therapy.
TLDR
It is indicated that the systemic clearance of teniposide is consistently increased two- to three-fold by concomitant phenobarbital or phenytoin therapy, and the consequent substantial reduction in systemic exposure may reduce tenipOSide's efficacy. Expand
Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia
TLDR
A comparison of the results of the present study on teniposide combined with amsacrine with those previously obtained for single-agent tenipOSide suggest that amSacrine produced little additive gastrointestinal toxicity. Expand
Effect of hydroxyzine on the transport of etoposide in rat small intestine
TLDR
The results showed that the transport of etoposide was significantly increased from the luminal site to the serosal site in the jejunum by 2- and 4-fold after 90 min in the presence of hydroxyzine and quinidine, respectively. Expand
Effects of verapamil on etoposide pharmacokinetics after intravenous and oral administration in rats
TLDR
The increased bioavailability of etoposide in the presence of verapamil should be taken into consideration for dosage regimens due to a potential drug interaction (DI). Expand
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
  • B. Lum, S. Kaubisch, +7 authors B. Sikic
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1992
TLDR
High-dose CsA produces significant increases in etoposide systemic exposure and leukopenia and these pharmacokinetic changes are consistent with inhibition byCsA of the multidrug transporter P-glycoprotein in normal tissues. Expand
Effects of morin on the pharmacokinetics of etoposide in rats.
TLDR
The pharmacokinetic parameters of etoposide intravenously administered were not significantly different from other groups, suggesting that CYP 3A-mediated metabolism and the P-gp mediated efflux of etoboside in the liver and kidney seemed not to be markedly inhibited by orally administered morin. Expand
EFEITOS CITOTÓXICOS DO TENIPOSIDE, UM DERIVADO SEMI-SINTÉTICO DAS EPIPODOFILOTOXINAS, SOBRE LINHAGENS CELULARES DE CARCINOMA RENAL HUMANO
TLDR
Assessment of teniposide at diverse schedules for its potential antitumor efficacy in an in vitro model of advanced renal cell carcinoma, a characteristically drug-resistant tumor indicates a need to evaluate alternative forms of treatment for this malignancy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 164 REFERENCES
Combination chemotherapy of the epipodophyllotoxin derivatives, Teniposide and Etoposide
TLDR
Analysis of VM26 in ascites and plasma suggests that the so-called “deep pharmacokinetic compartment” represents ascites equivalent space and that the plasma concentration represents VM26 as free and protein-bound drug in kinetic distinguishable compartments. Expand
VP16-213 (Etoposide)
  • F. Cavalli
  • Medicine
  • Cancer Chemotherapy and Pharmacology
  • 2004
TLDR
The phase-I-II trials with VP16-213 might be viewed as an example of the methodological difficulties encountered in the clinical evaluation of new agents, and some pitfalls can probably be avoided by implementing a more stringent and standardized methodology. Expand
Bioavailability and pharmacokinetics of etoposide (VP-16).
TLDR
Significant intersubject and intrasubject variation was observed in intravenous and oral pharmacokinetics and oral bioavailability in cancer patients, which could be related to intrapatient and interpatient differences in nonrenal clearance and the inherent patient and disease status problems in evaluating the Pharmacokinetics of anticancer drugs. Expand
Pharmacokinetics of etoposide in gestochoriocarcinoma.
Etoposide (VP16) levels were determined by high-performance liquid chromatography assay in plasma, urine, and surgical specimens of patients with choriocarcinoma undergoing surgery after a dose ofExpand
Teniposide (VM26) disposition in children with leukemia.
TLDR
A significant relationship between serum alkaline phosphatase and systemic clearance, elimination rate constant, and area under the concentration-time curve was found, suggesting that liver function influences the disposition of this anticancer drug in humans. Expand
Pharmacokinetics of teniposide in patients with ovarian cancer.
TLDR
Pharmacokinetics of teniposide after each of three doses were investigated by high-performance liquid chromatographic assay in eight patients with ovarian cancer with normal liver and renal functions, finding VM26 levels in ascites were lower than those in plasma in the first hours after drug administration, but by 24 hours they were similar or slightly higher. Expand
Pharmacokinetics of high dose etoposide (VP 16-213).
TLDR
It was concluded that etoposide is strongly bound in the peripheral compartment, and the plasma concentration time curve shows a tri-phasic decay. Expand
High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection.
A high-performance liquid chromatographic (HPLC) assay was developed for the quantitation of two structurally similar and highly active anticancer drugs, etoposide (I) and teniposide (II), and theirExpand
Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.
TLDR
It is suggested that the epipodophyllotoxins exert their anti-cancer effects by "poisoning" type II topoisomerase without binding to DNA, which may be analogous to those of nalidixic acid in bacteria. Expand
4'-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action.
TLDR
The new podophyllotoxin glucoside derivative VM 26 was found to have a high cytostatic activity in cell cultures and inhibits entry of cells into mitosis or destroys cells preparing for mitosis, one of its biochemical effects is inhibition of thymidine uptake. Expand
...
1
2
3
4
5
...